Spir2; a novel QTL on chromosome 4 contributes to susceptibility to pneumococcal infection in mice

BMC Genomics

Research Article

Vitor E Fernandes¹  Peter W Andrew¹  Daniel R Neill²  Aras Kadioglu²  Paul Denny³  Laura Wisby³ 

[1] Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK;Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK;Department of Clinical Infection Microbiology & Immunology, Institute of Infection & Global Health, University of Liverpool, Liverpool, UK;MRC Mammalian Genetics Unit, Harwell, OX11 0RD, Oxon, UK;

关键词: Streptococcus pneumoniae;    Host susceptibility;    Host genetics;    Quantitative trait loci;    Model organism;    Mouse;    Bacterial infection;    Inflammation;   

DOI  :  10.1186/1471-2164-14-242

 received in 2012-09-18, accepted in 2013-04-04,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundStreptococcus pneumoniae causes over one million deaths worldwide annually, despite recent developments in vaccine and antibiotic therapy. Host susceptibility to pneumococcal infection and disease is controlled by a combination of genetic and environmental influences, but current knowledge remains limited.ResultsIn order to identify novel host genetic variants as predictive risk factors or as potential targets for prophylaxis, we have looked for quantitative trait loci in a mouse model of invasive pneumococcal disease. We describe a novel locus, called Streptococcus pneumoniae infection resistance 2 (Spir2) on Chr4, which influences time to morbidity and the development of bacteraemia post-infection.ConclusionsThe two quantitative trait loci we have identified (Spir1 and Spir2) are linked significantly to both bacteraemia and survival time. This may mean that the principle cause of death, in our model of pneumonia, is bacteraemia and the downstream inflammatory effects it precipitates in the host.

【 授权许可】

Unknown   
© Wisby et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.